• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I型神经纤维瘤病患儿及青少年中丛状神经纤维瘤的患病率。

Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis.

作者信息

Darrigo Luiz G, Geller Mauro, Bonalumi Filho Aguinaldo, Azulay David R

机构信息

Universidade de São Paulo (USP), São Paulo, SP, Brazil.

出版信息

J Pediatr (Rio J). 2007 Nov-Dec;83(6):571-3. doi: 10.2223/JPED.1718. Epub 2007 Nov 30.

DOI:10.2223/JPED.1718
PMID:18046492
Abstract

OBJECTIVE

To assess prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis and its malignant potential.

METHODS

A retrospective study was conducted through analysis of the database at Centro Nacional de Neurofibromatose [Brazilian Neurofibromatosis Center], collected from the following reference services between 1996 and 2004: Instituto de Dermatologia Prof. Rubem David Azulay da Santa Casa de Misericórdia do Rio de Janeiro, Instituto de Pediatria e Puericultura Martagão Gesteira da Universidade Federal do Rio de Janeiro and Department of Immunology and Microbiology at Faculdade de Medicina de Teresópolis.

RESULTS

Over that period, 104 patients aged between 1-17 years were admitted with clinical diagnosis of type I neurofibromatosis. Of these, 53 were male and 51 were female, and 28 patients (15 male and 13 female) had plexiform neurofibroma (26.9%). Division by age group resulted in 21.42% (six) between 1-5 years; 35.71% (10) between 6-12 years and 42.85% (12) between 13-17 years. Of the 104 patients, two developed a malignant peripheral nerve sheath tumor (1.92%).

CONCLUSIONS

Plexiform neurofibromas are relatively common manifestations in patients with type I neurofibromatosis and may be a cause of significant increase in morbidity and mortality among patients. In this study, we conclude that frequency of plexiform neurofibroma and its malignant potential in the population studied is in agreement with data from the international literature.

摘要

目的

评估I型神经纤维瘤病患儿及青少年中丛状神经纤维瘤的患病率及其恶变潜能。

方法

通过分析巴西国家神经纤维瘤病中心(Centro Nacional de Neurofibromatose)的数据库进行一项回顾性研究,该数据库收集了1996年至2004年间以下参考机构的数据:里约热内卢仁慈圣母医院鲁本·大卫·阿祖莱皮肤科研究所、里约热内卢联邦大学马尔塔冈·热斯泰拉儿科与儿童保健研究所、特雷索波利斯医学院免疫学与微生物学系。

结果

在该时期,104例年龄在1至17岁之间的患者因I型神经纤维瘤病的临床诊断入院。其中,男性53例,女性51例,28例患者(男性15例,女性13例)患有丛状神经纤维瘤(26.9%)。按年龄组划分,1至5岁之间为21.42%(6例);6至12岁之间为35.71%(10例);13至17岁之间为42.85%(12例)。在这104例患者中,2例发生了恶性外周神经鞘瘤(1.92%)。

结论

丛状神经纤维瘤是I型神经纤维瘤病患者相对常见的表现,可能是患者发病率和死亡率显著增加的原因。在本研究中,我们得出结论,在所研究人群中丛状神经纤维瘤的发生率及其恶变潜能与国际文献数据一致。

相似文献

1
Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis.I型神经纤维瘤病患儿及青少年中丛状神经纤维瘤的患病率。
J Pediatr (Rio J). 2007 Nov-Dec;83(6):571-3. doi: 10.2223/JPED.1718. Epub 2007 Nov 30.
2
Association between benign and malignant peripheral nerve sheath tumors in NF1.1型神经纤维瘤病中良性与恶性周围神经鞘膜瘤的关联
Neurology. 2005 Jul 26;65(2):205-11. doi: 10.1212/01.wnl.0000168830.79997.13.
3
Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.1型神经纤维瘤病中丛状神经纤维瘤的基于临床的研究。
Am J Med Genet. 2000 May 15;92(2):132-5.
4
Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?丛状神经纤维瘤是I型神经纤维瘤病的特征性表现吗?
Laryngoscope. 2004 Aug;114(8):1410-4. doi: 10.1097/00005537-200408000-00018.
5
Oral manifestations of neurofibromatosis type 1 in children with facial plexiform neurofibroma: report of three cases.1型神经纤维瘤病患儿面部丛状神经纤维瘤的口腔表现:3例报告
J Clin Pediatr Dent. 2015 Winter;39(2):168-71. doi: 10.17796/jcpd.39.2.972220046g774534.
6
Single-stage total endoscopic resection of a plexiform neurofibroma of the maxillary sinus in a child with type 1 neurofibromatosis.1型神经纤维瘤病患儿上颌窦丛状神经纤维瘤的单阶段全内镜切除术
Int J Pediatr Otorhinolaryngol. 2010 Apr;74(4):426-9. doi: 10.1016/j.ijporl.2009.12.012. Epub 2010 Jan 13.
7
Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, prevalence and clinical significance.1型神经纤维瘤病中组织病理学发育异常的神经纤维瘤:诊断标准、患病率及临床意义
Br J Dermatol. 2008 May;158(5):1008-12. doi: 10.1111/j.1365-2133.2008.08494.x. Epub 2008 Mar 20.
8
Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.神经纤维瘤病 1 型伴眼眶颞部丛状神经纤维瘤患儿的视觉预后。
Am J Ophthalmol. 2013 Jun;155(6):1089-1094.e1. doi: 10.1016/j.ajo.2013.01.011. Epub 2013 Feb 26.
9
Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan.采用定性研究方法,对1型神经纤维瘤病相关丛状神经纤维瘤(pNF)患者在其一生中所关注的问题进行概念化。
Am J Med Genet A. 2017 Jan;173(1):79-87. doi: 10.1002/ajmg.a.37987. Epub 2016 Sep 26.
10
Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [ F]FDG-PET imaging. Is it of value in asymptomatic patients?利用[F]FDG-PET成像监测1型神经纤维瘤病儿童和青少年的丛状神经纤维瘤。对无症状患者有价值吗?
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26733. Epub 2017 Aug 3.

引用本文的文献

1
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.阿拉伯海湾合作委员会地区1型神经纤维瘤病的诊断与管理:挑战与建议
Front Oncol. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176. eCollection 2024.
2
Kinase Inhibitors in Genetic Diseases.激酶抑制剂在遗传性疾病中的应用。
Int J Mol Sci. 2023 Mar 9;24(6):5276. doi: 10.3390/ijms24065276.
3
Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.神经纤维瘤病:COVID-19时代的新临床挑战
Biomedicines. 2022 Apr 19;10(5):940. doi: 10.3390/biomedicines10050940.
4
Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1.491 例巴西神经纤维瘤病 1 型患者的流行病学特征和临床特征。
Brain Behav. 2022 Jun;12(6):e2599. doi: 10.1002/brb3.2599. Epub 2022 May 4.
5
Cordycepin inhibits the proliferation of malignant peripheral nerve sheath tumor cells through the p53/Sp1/tubulin pathway.虫草素通过p53/Sp1/微管蛋白途径抑制恶性外周神经鞘膜瘤细胞的增殖。
Am J Cancer Res. 2021 Apr 15;11(4):1247-1266. eCollection 2021.
6
The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.PlexiQoL 的发展:一种用于 1 型神经纤维瘤病相关丛状神经纤维瘤的成年患者报告结局测量工具。
Mol Genet Genomic Med. 2020 Dec;8(12):e1530. doi: 10.1002/mgg3.1530. Epub 2020 Oct 21.
7
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.神经纤维瘤病 1 型法国国家指南,基于自 1966 年以来的广泛文献回顾。
Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3.
8
Pigmented (melanotic) diffuse neurofibroma of the back in neurofibromatosis type 1.1型神经纤维瘤病中背部的色素沉着(黑素性)弥漫性神经纤维瘤
GMS Interdiscip Plast Reconstr Surg DGPW. 2018 Aug 3;7:Doc04. doi: 10.3205/iprs000124. eCollection 2018.
9
Moyamoya syndrome associated with neurofibromatosis type 1 in a pediatric patient.一名儿科患者中与1型神经纤维瘤病相关的烟雾综合征。
An Bras Dermatol. 2017 Nov-Dec;92(6):870-873. doi: 10.1590/abd1806-4841.20176829.
10
Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.苹果酸舒尼替尼用于治疗丛状神经纤维瘤的临床前证据。
Pediatr Blood Cancer. 2016 Feb;63(2):206-13. doi: 10.1002/pbc.25763. Epub 2015 Sep 16.